Fady Ibraham Malik Sells 15,547 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik sold 15,547 shares of the business’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $65.11, for a total transaction of $1,012,265.17. Following the completion of the sale, the executive vice president now owns 137,056 shares in the company, valued at $8,923,716.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Fady Ibraham Malik also recently made the following trade(s):

• On Tuesday, April 9th, Fady Ibraham Malik sold 32,605 shares of Cytokinetics stock. The stock was sold at an average price of $74.31, for a total transaction of $2,422,877.55.
• On Tuesday, March 5th, Fady Ibraham Malik sold 32,604 shares of Cytokinetics stock. The shares were sold at an average price of $67.56, for a total transaction of $2,202,726.24.

Cytokinetics Stock Performance

Shares of NASDAQ CYTK opened at $65.27 on Thursday. The business has a 50 day simple moving average of $67.82 and a 200 day simple moving average of $61.66. Cytokinetics, Incorporated has a 52 week low of $25.98 and a 52 week high of $110.25. The stock has a market cap of $6.83 billion, a price-to-earnings ratio of -11.98 and a beta of 0.72.

Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.35). The business had revenue of $1.70 million for the quarter, compared to the consensus estimate of $7.62 million. During the same period last year, the company earned ($1.45) earnings per share. The firm’s quarterly revenue was down 10.5% on a year-over-year basis. On average, analysts predict that Cytokinetics, Incorporated will post -4.5 EPS for the current year.

Institutional Investors Weigh In On Cytokinetics

A number of large investors have recently bought and sold shares of the business. Entropy Technologies LP lifted its position in shares of Cytokinetics by 110.6% in the first quarter. Entropy Technologies LP now owns 19,433 shares of the biopharmaceutical company’s stock worth $1,362,000 after buying an additional 10,205 shares during the last quarter. ProShare Advisors LLC boosted its position in Cytokinetics by 22.3% during the first quarter. ProShare Advisors LLC now owns 29,167 shares of the biopharmaceutical company’s stock worth $2,045,000 after purchasing an additional 5,313 shares during the period. US Bancorp DE grew its holdings in Cytokinetics by 67.2% during the first quarter. US Bancorp DE now owns 5,634 shares of the biopharmaceutical company’s stock valued at $395,000 after purchasing an additional 2,265 shares during the last quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. lifted its stake in shares of Cytokinetics by 33.8% in the first quarter. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. now owns 461,018 shares of the biopharmaceutical company’s stock worth $32,322,000 after buying an additional 116,534 shares during the last quarter. Finally, Inspire Investing LLC boosted its holdings in shares of Cytokinetics by 13.5% during the 1st quarter. Inspire Investing LLC now owns 5,087 shares of the biopharmaceutical company’s stock worth $357,000 after buying an additional 605 shares during the period.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on CYTK shares. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price target on shares of Cytokinetics in a report on Wednesday. Truist Financial reaffirmed a “buy” rating and set a $86.00 target price on shares of Cytokinetics in a report on Monday, April 8th. UBS Group cut Cytokinetics from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $61.00 to $92.00 in a research note on Wednesday, January 24th. Mizuho reduced their price objective on shares of Cytokinetics from $103.00 to $99.00 and set a “buy” rating for the company in a research note on Wednesday, March 6th. Finally, Oppenheimer reissued an “outperform” rating and issued a $107.00 target price on shares of Cytokinetics in a research report on Monday, March 4th. One analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, Cytokinetics currently has a consensus rating of “Moderate Buy” and a consensus price target of $79.33.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.